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Abstract 
Major histocompatibility complex class II (MHC-II) molecules are expressed on the surface of professional 
antigen presenting cells where they display peptides to T helper cells, which orchestrate the onset and 
outcome of many host immune responses. Understanding which peptides will be presented by the MHC-II 
molecule is therefore important for understanding the activation of T helper cells and can be used to identify 
T-cell epitopes. We here present updated versions of two MHC class II peptide binding affinity prediction 
methods, NetMHCII and NetMHCIIpan. These were constructed using an extended data set of quantitative 
MHC-peptide binding affinity data obtained from the Immune Epitope Database covering HLA-DR, HLA-DQ, 
HLA-DP and H-2 mouse molecules. We show that training with this extended data set improved the 
performance for peptide binding predictions for both methods. Both methods are publicly available at 
www.cbs.dtu.dk/services/NetMHCII-2.3 and www.cbs.dtu.dk/services/NetMHCIIpan-3.2.  
 
Introduction 
Major histocompatibility complex class II (MHC-II) molecules are found on the surface of antigen presenting 
cells where they present peptides derived from extracellular proteins to T helper cells (1). Many peptide-MHC 
complexes are presented on the surface of antigen presenting cells, but only peptides recognized by T-cell 
receptors (TCRs) will trigger an immune response, and are referred to as T-cell epitopes. Identifying T-cell 
epitopes is important for the general understanding of cellular immunity and the design of peptide-based 
diagnostics, therapeutics, and vaccines (2). The MHC-II molecule is a heterodimeric glycoprotein that consists 
of an - and a -chain. In humans, these two chains are encoded in the human leukocyte antigen (HLA) gene 
complex in one of three loci called: HLA-DR, -DP and -DQ (3). In mice, the MHC-II chains are encoded in the 
histocompatibility 2 (H-2) locus. Each locus is comprised of many different allelic variants which makes the 
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MHC-II molecule highly polymorphic (4). Peptides presented by the MHC-II molecule bind to a binding groove 
formed by residues of the MHC - and the -chain. The peptide-binding groove is open at both ends and 
therefore allows binding of peptides with different lengths (5). Even though the MHC-II molecule can 
accommodate peptides of variable lengths the most abundant peptides found in nature are between 13 and 
25 residues long (6). The part of the peptide ligand that primarily interact with the MHC binding groove is 
called the peptide binding core and it usually 9 amino acids long (7) with anchor residues at positions P1, P4, 
P6 and P9 (8). The peptide-MHC binding affinity is primarily determined by the amino acid sequence of the 
peptide-binding core. However, it has been shown that peptide flanking regions (PFRs) on either side of the 
binding core affect peptide-MHC binding and, thereby ultimately also influence the peptide immunogenicity 
(9),(7).  
There are therefore many factors that make it difficult to predict peptide binding affinities to MHC-II 
molecules, including the polymorphic nature of MHC-II molecules, the variations in peptide length, the 
influence of the peptide flanking regions and the identification of the correct peptide binding core. All these 
factors complicate the task of predicting peptide binding affinities to MHC-II molecules; most methods 
therefore still have a low performance compared to MHC class I (MHC-I) peptide binding prediction methods. 
Earlier work has demonstrated that the prediction performance of both NetMHCII and NetMHCIIpan is 
dependent on the amount of peptide binding data (10),(11) and one would therefore expect the two methods 
to improve in performance if retrained on an extended peptide binding data set. We have here investigated if 
this is indeed the case.  
Identifying T-cell epitopes is difficult because of the large diversity in potentially binding peptides. However, as 
peptide-MHC binding is a prerequisite for T-cell immunogenicity, and multiple studies have shown that there is 
a strong correlation between MHC peptide binding strength and peptide immunogenicity (12)(13)(14). It is 
therefore desirable to have accurate and reliable peptide binding affinity prediction methods that can be used 
for in silico screening peptides with the purpose of identifying T-cell epitopes that match MHC-II molecules in a 
given host. Given this, many different methods have been developed, including NetMHCII (15), NetMHCIIpan 
(16), TEPITOPE (17), TEPITOPEpan (18),PROPRED (19), RANKPEP (20)(21) and SVRMHC (22). Both NetMHCII 
(15) and NetMHCIIpan (16) have been shown to be among the best methods for predicting binding affinities to 
MHC class II molecules (2),(8),(23). These two methods are trained using the NNAlign framework (15),(24),(25) 
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and are based on ensembles of artificial neural networks which are trained on quantitative peptide binding 
affinity data from IEDB (26). One of the main differences between NetMHCII and NetMHCIIpan is that 
NetMHCII is a collection of individual networks for each MHC molecule whereas NetMHCIIpan contains a single 
universal network that can predict peptide binding affinities for all MHC molecules of known protein 
sequence. 
NetMHCII and NetMHCIIpan predict peptide binding affinities to MHC class II molecules covering HLA-DR, HLA-
DQ, HLA-DP and H-2 mouse molecules. The main difference between the two methods is that NetMHCII only 
predict peptide binding affinities to MHC molecules for which it has been trained, while NetMCHIIpan can 
predict peptide binding affinities to any MHC molecule with a known protein sequence. As mentioned above 
there is a strong correlation between MHC binding strength and peptide immunogenicity and the two 
methods have been used extensively as a guide to identify T-cell epitopes which can be used in the design of 
peptide-based diagnostics, therapeutics, and vaccines. 
In this paper, we present updated versions of our binding affinity prediction methods, NetMHCII and 
NetMHCIIpan, trained on an extended data set of more than 100,000 quantitative peptide-binding 
measurements from IEDB (26), covering 36 HLA-DR, 27 HLA-DQ, 9 HLA-DP, as well as 8 mouse MHC-II 
molecules. We then evaluate the performance of these new versions using a set of large scale benchmarks to 
investigate how the extended data set improves the predictive performance of the two both methods.  
 
Materials and methods 
Data sets 
The data set used to generate the new versions of NetMHCII and NetMHCIIpan contains peptide-MHC II 
binding affinities retrieved from the Immune Epitope Database (IEDB, www.iedb.org) in 2016. All data points 
are experimental IC50 binding values which were log-transformed to fall in the range between 0 and 1 using 
the relation 1−log(IC50nM)/log(50,000) as explained in (27). This 2016 data set contains 134,281 data points, 
covering 36 HLA-DR, 27 HLA-DQ, 9 HLA-DP and 8 H-2 molecules. The data set was split into five groups by 
clustering the common motif of peptides as described by Nielsen et al. (28) and these five groups were used 
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for a five-fold cross validation. This 2016 data set is publicly available at 
www.cbs.dtu.dk/suppl/immunology/NetMHCIIpan-3.2. The data set used to develop the previous versions of 
NetMHCII and NetMHCIIpan is available at www.cbs.dtu.dk/suppl/immunology/NetMHCIIpan-3.0.  
A summary of the data included in the 2013 and 2016 data sets is shown in Table 1 and a description of the full 
2016 data set is available in supplementary table 1.  
 
Network training  
The NetMHCII method was implemented as described by Nielsen and Lund (15) and the NetMHCIIpan method 
was implemented as described by Andreatta et al. (16). NetMHCII is an allele-specific method that contains a 
specific predictor for each MHC molecule in the data set and it can therefore only predict binding affinities for 
MHC molecules found in the training data, whereas NetMHCIIpan is a pan-specific method that can make 
predictions for any MHC molecule of known protein sequence. To achieve its pan-specificity, NetMHCIIpan 
incorporates information about the MHC-II molecule, using a pseudo sequence consisting of residues which 
are considered important for peptide binding. This pseudo sequence is constructed using the method 
described by Karosiene et al. (11) and is composed of 34 residues, 15 residues from the -chain and 19 
residues from the -chain. Both methods were trained using a five-fold cross-validation setup. For each fold, 
we generate a network ensemble of individual networks trained without early stopping for 500 cycles with 10, 
15, 40 and 60 hidden neurons using 10 different initial configurations, generating a total of 40 networks. This 
was done for each of the 5 training/test set combination leading to a total of 200 networks. The peptide and 
the MHC pseudo sequence was encoded using the BLOSUM50 matrix and the peptide flanking regions (PFR) 
was encoded using the average BLOSUM scores on a maximum window of three amino acids at either end of 
the binding core (29). For each peptide core, the input to the neural network thus consisted of the peptide 
core (9 × 20 = 180 inputs), the PFRs (2 × 20 = 40 inputs), the peptide length (2 inputs), the length of the C- and 
N- terminal PFR’s (2 × 2 = 4 inputs), resulting in a total of 226 input values for NetMHCII and 906 for 
NetMHCIIpan (an additional 34 × 20 = 680 input values from the pseudo sequence).  
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Binding core predictions 
To improve the binding core predictions, we include the offset correction step to both NetMHCII and 
NetMHCIIpan as described by Andreatta et al. (16) and we evaluated the performance of this offset correction 
using the benchmark data set of 51 crystal structures of peptide-MHC class II complexes as described in (16). 
 
Performance measures 
The predictive performance of the different methods was measured using the area under the ROC curve 
(AUC). To classify peptides into binders and non-binders, a binding threshold of 500 nM was used, classifying 
all peptides with a IC50 binding value below 500 nM as binders. All performance values shown in this paper 
are averages of the performance per MHC molecule using only molecules with more than 20 peptides and at 
least 4 binders.  
 
Leave-one-molecule-out network training 
In order to assess the predictive performance of NetMHCIIpan in the situation where a molecule is not part of 
the training data, a leave-one-molecule-out (LOMO) approach was applied.  
To estimate LOMO performance for MHC molecule X, the NetMHCIIpan networks were trained using the five-
fold cross-validation setup from above. In the LOMO cross-validation setup all binding data from molecule X 
were removed from the training sets and all test set only include binding data from molecule X. This setup 
ensures that the method is trained without peptides binding to molecule X and it can therefore be used to 
evaluate the ability of the method to predict peptide binding of uncharacterized MHC-II molecules. 
 
Nearest neighbor distance calculation  
The nearest neighbor distance is estimated from the alignment score of the HLA pseudo sequences using the 
relation 
     
            
 . In this equation s(A,B) is the BLOSUM50 alignment score between the pseudo 
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sequences for MHC molecule A and B, respectively (29). Nearest neighbors are found from the subset of 
molecules characterized with at least 50 data points and at least 10 binders. 
 
Sequence logos  
Sequence logos were constructed from the predicted binding cores of the top 1% strongest predicted binders 
using 200,000 natural random 15-mer peptides and was visualized using Seq2Logo (30) with default settings. 
 
Generation of HLA-II distance trees 
The HLA-II distance tree was generated for each of the HLA-DR, -DQ and -DP molecule in our data set using 
MHCCluster (31). To make the tree we first predicted the binding affinity for 200,000 natural random 15-mer 
peptides using the new version of NetMHCIIpan. We then used MHCCluster to find the functional similarity 
between any two MHC molecules. MHCCluster calculates the similarity between two MHC molecules by 
correlating the union of the predicted top 10 % strongest binding peptides. Using the bootstrap method in 
MHCCluster we generated 100 distance matrices and converted these to distance trees using the unweighted 
pair group method with arithmetic mean (UPGMA) clustering. These trees were then combined into a 
consensus tree and visualized in SplitsTree (32). Sequence logos were constructed as explained above.  
 
T-cell epitope benchmark  
A set of MHC-II restricted T-cell epitopes identified by multimer/tetramer staining assays was downloaded 
from IEDB. Only fully typed restrictions were included; that is, fully typed - and -chains for HLA-DQ and HLA-
DP, and a fully typed -chain for HLA-DR (where the alpha chain is invariant). Epitopes with non-natural amino 
acids were excluded. Also, epitopes with identical match to the peptides in the training data were excluded. 
The source protein sequence for each epitope was identified by mapping the annotated IEDB protein ID to the 
NCBI protein database. The final validation data set consisted of 1698 epitopes, restricted to 33 distinct MHC 
class II molecules. For performance evaluation, the epitope source protein was split into overlapping peptides 
of the length of the epitope, and AUC and Frank values were calculated for each epitope-MHC pair annotating 
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the epitopes as positive and all other as negatives. Here, Frank is the ratio of the number of peptides with a 
prediction score higher than the positive peptide to the number of peptides contained within the source 
protein. Hence, the Frank value is 0 if the positive peptide has the highest prediction value of all peptides 
within the source protein and a value of 0.5 in cases in which an equal number of peptides has a higher and 
lower prediction value compared with the positive peptide. 
 
Results 
Comparing NetMHCII and NetMHCIIpan on a shared evaluation set 
Using the data set from 2016, we retrained NetMHCII (15) and NetMHCIIpan (11) using a five-fold cross-
validation setup to generate two new versions of these methods, named NetMHCII-2.3 and NetMHCIIpan-3.2. 
We then investigated how these new versions performed compared to the previous versions, which are 
NetMHCII-2.2 and NetMHCIIpan-3.1, trained on the 2013 data set. To make the comparison, we used the same 
five-fold cross-validation setup and compared peptide data points in common between the 2013 and 2016 
data sets. The result from this analysis in shown in Table 2.  
The new versions of NetMHCII and NetMHCIIpan improved performance compared to the older versions (table 
2). This performance gain is however not statistically significant (p>0.1 in both cases). Another interesting 
point is that the allele-specific NetMHCII-2.3 obtains a higher average performance than the pan-specific 
NetMHCIIpan-3.2. This effect will be discussed later.  
 
Performance of NetMHCIIpan on new data points for common MHC molecules  
Using the five-fold cross-validation setup, we then evaluated the performance of the two versions of NetMHCII 
and NetMHCIIpan using only the subset of new peptides for the MHC molecules common between the old and 
the new data sets. The result of this analysis is shown in table 3 and it demonstrates a significant gain in 
predictive performance of the new versions (NetMHCII, p-value < 0.005 and NetMHCIIpan, p-value < 0.001, 
using paired t-test). This result thus underlines the importance of expanding the size of the training data even for 
previously characterized MHC molecules.  
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Binding core predictions 
We evaluated the accuracy for binding core identification of the two updated MHC class II binding 
prediction methods on the data set of peptide-MHC crystal structures described by Andreatta et al. 
(16). Overall we find that i) the inclusion of the offset correction described earlier to align the 
individual network in the network ensemble has a substantial impact on the accuracy of binding core 
identification for both methods, and ii) that the overall accuracy of both methods is improved 
compared to the earlier version. For details see supplementary table 2.  
 
Performance of a consensus method 
For predicting binding affinities to MHC class I, it has been shown that a simple combination of the predictions 
from NetMHC (27) and NetMHCpan (10) gives a higher performance than using each method individually (33). 
We therefore made a similar combination of the predictions from NetMHCII-2.3 and NetMHCIIpan-3.2 to 
investigate if the performance could be improved for MHC class II using this consensus approach. In the 
consensus method, we use an average of the prediction scores (values between 0 and 1) from NetMHCII-2.3 
and NetMHCIIpan-3.2 to define the consensus method. The result of this analysis is shown in figure 1 and 
detailed performance values are found in supplementary table 3. Figure 1A shows that the combination of 
NetMHCII-2.3 and NetMCHIIpan-3.2 has a significantly improved performance compared to each individual 
method and figure 1B shows that NetMHCIIpan-3.2 outperforms NetMHCII-2.3 especially for MHC molecules 
where only few peptides are found in the data set.  
 
Performance of NetMHCIIpan for previously uncharacterized MHC molecules 
For NetMHCIIpan, we also tested the performance on MHC molecules that were not part of the 2013 data set 
(see table 4). As expected, we observed that the new version of NetMHCIIpan had a significant increase in the 
predictive performance when compared to the previous version of NetMHCIIpan (p-value = 3.610
-5
, using a 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
paired t-test); this result thus demonstrates the importance of expanding the allotypic coverage of the training 
data. 
 
Leave-one-molecule-out performance 
The pan-specific method is capable of making predictions for uncharacterized MHC molecules, so to assess the 
predictive performance of the NetMHCIIpan method in these situations we conducted a leave-one-molecule-
out (LOMO) experiment. In the LOMO, the binding data for the MHC molecule in question were excluded from 
training and the resulting model were then evaluated using only binding data for the MHC molecule in 
question (for details see Materials and Methods). The LOMO experiment was made for all MHC molecules 
shared between the 2013 and the 2016 data sets, and the performance evaluated on peptides shared between 
the two data sets. The result of this LOMO benchmark is shown in table 5, together with the pseudo distances 
of the MHC molecule to each of the two training data sets estimated from the nearest neighbor sequence 
similarity as described in Materials and Methods. 
Table 5 shows an increased performance for NetMHCIIpan-3.2-LOMO compared to netMHCIIpan-3.1-LOMO. 
This gain is in general most pronounced for the MHC molecules that share a decrease in the pseudo sequence 
distance. 
To further investigate this last observation, the LOMO performance evaluation was extended to include all 
MHC molecules in the 2016 data set. The result from this analysis is shown in figure 2 with a scatterplot of the 
relationship between the distance to the nearest neighbor in the training data set and the LOMO performance. 
The complete data used to create figure 2 can be found in supplementary table 4. The figure shows that the 
HLA-DQ and the HLA-DP molecules have close nearest neighbors while the HLA-DR and H-2 molecules tend to 
have more distant neighbors. This figure also demonstrates a weak but statistically significant (p-value of 0.04 
with exact permutation test) correlation between the LOMO performance and the distance to the nearest 
neighbor in the training data. This is in agreement with earlier findings for both MHC-I and MHC-II molecules 
(10)(11) and shows how the predictive performance of the pan-specific method depends on the distance to 
the nearest neighbor.  
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Distance tree for HLA molecules  
Having arrived at the final retrained versions of NetMHCIIpan, we next use the MHCCluster method (31) to 
evaluate the similarities of binding motives between the HLA molecules included in the 2016 training data. In 
short, the MHCCluster method estimates the similarity between two MHC molecules using the correlation 
between predicted binding values for a large set of random natural peptides. The similarity is 1 if the two 
molecules have a perfect binding specificity overlap and −1 if the two molecules share no specificity overlap 
(for details see Materials and Methods). Comparing the binding pattern similarity between any two HLA class II 
molecule in the 2016 training data, we constructed the distance tree shown in figure 3. This figure confirms 
the earlier findings by Karosiene et al. (11), i) the different loci shows limited overlap in binding preference, ii) 
HLA-DP is less diverse compared to HLA-DQ and HLA-DR, and iii) the diversity of HLA-DQ can largely be split 
into 3 groups; one with preference for negatively charged amino acids toward to the C-terminal, one with a 
preference for positively charged amino acids towards the C-terminus, and one with preference for small 
amino acids at the anchor positions. 
 
T-cell epitope benchmark  
We next evaluated the predictive performance of the two NetMHCIIpan methods on an IEDB T-cell epitope 
data set. We queried the IEDB for MHC-II restricted epitopes identified by tetramer/multi-mer staining, which 
is the gold-standard for epitope identification with known MHC restriction. For each epitope-MHC class II pair, 
we calculated AUC and Frank values for the two NetMHCIIpan methods by predicting binding affinities to the 
MHC class II restriction element of the epitope for all overlapping peptides with the same length as the 
epitope in the source protein sequence, annotating the epitope as positive and the remaining peptides as 
negative. This annotation is very stringent since peptides that share the same ligand binding-core are counted 
as negatives even though they could be presented by the human MHC molecule; the setup will therefore most 
likely underestimate the predictive performance. The details from this analysis are found in supplementary 
table 5 and the results are summarized in figure 4.  
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Recall that the Frank value is 0 if the positive peptide has the highest prediction value of all peptides within the 
source protein, and a value of 0.5 in cases where an equal number of peptides has a higher and lower 
prediction value compared to the positive peptide. Figure 4 A shows that the Frank score for NetMHCIIpan-3.1 
is significant lower than NetMHCIIpan-3.1. It further shows that NetMHCIIpan-3.2 has a median below 0.2 
indicating that the positive peptide was found among the top 20% of the peptides from the source protein if 
sorted on their predicted peptide binding affinity. Figure 4 B demonstrates a significant improvement in the 
AUC performance of NetMHCIIpan-3.2 compared to NetMHCIIpan-3.1. We speculate that the gain in predictive 
performance of NetMHCIIpan-3.2 could be attributed to at least two factors, the inclusion of binding data for 
additional MHC class II molecules in the training data, and the expansion of the number of data points for MHC 
class II molecules already included in the old training data. Figures 4 C and D quantify that both of these 
factors indeed contribute to the performance gain. Figure 4 C shows the performance gain as a function of the 
change in distance of the query molecule to the nearest neighbor of the training data. From this plot, we see 
that the gain in predictive performance is related to a decrease in the nearest neighbor distance, and hence 
directly related to the inclusion of binding data for additional MHC class II molecules in the new data set. 
Figure 4 D shows the performance gain as a function of the change in the number of data points between the 
two data sets used for training. We here only include molecules shared between the two data sets used for 
training NetMHCIIpan-3.1 and NetMHCIIpan-3.2, as we in the previous analysis demonstrated how the 
distance to the nearest neighbor influences the performance. Figure 4 D shows that the gain in performance is 
correlated to change in the number of data points for the given MHC molecules. This indicates that the 
performance gain of the new NetMHCIIpan version is also driven by the increase in the number of data points 
for molecules already included in the 2013 data set. The one data point in Figure 4 C and D with increased 
nearest neighbor distance and decreased number of data points corresponds to the HLA-DPA10103-DPB10201 
molecule for which faulty data was removed in the 2016 dataset.  
 
Discussion  
The genomic region encoding the MHC-II molecule is extremely polymorphic comprising several thousand 
alleles and it is therefore difficult to produce enough experimental data to characterize the peptide binding 
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preference for all existing MHC-II molecules. Because of this, most MHC class II molecules are still only 
represented with very few or no binding data, limiting the coverage and performance of previous binding 
affinity prediction methods. We have therefore updated our two binding affinity prediction methods, 
NetMHCII and NetMHCIIpan using updated and extended data sets. For several large-scale benchmarks, this 
improved the predictive performance for both methods.  
 
Comparing NetMHCII and NetMHCIIpan  
Using the data points shared by the old and the updated data sets, we first compared the different versions of 
NetMHCII and NetMHCIIpan. We showed how the new versions of the methods outperformed the previous 
versions both for NetMHCII and NetMHCIIpan. We then evaluated the performance of the two versions of the 
methods using only “new” peptides, for the MHC molecules covered both by the old and the updated data 
sets. The result of this analysis showed that both methods on this data set gained a significant improvement in 
the predictive performance, thus supporting the importance of expanding the size of the training data even for 
MHC molecules already characterized by binding data. When evaluating new peptides one has to keep in mind 
that MHC binding predictors are often used to select peptides for experimental validation and new data sets 
may be less diverse than historic data sets generated sampling the entire space of a given set of protein 
sequences (34).  
The main difference between NetMHCII and NetMHCIIpan is that NetMHCII is an allele-specific method trained 
separately for each MHC molecule, whereas NetMHCIIpan is a pan-specific method that contains a single 
ensemble of networks using information from all MHC molecules in the data set. We would therefore expect 
that the allele-specific method outperforms the pan-specific method for MHC molecules where sufficient data 
is available to accurately characterize the binding motif, and we would expect the pan-specific method to 
outperform the allele-specific method when data is scarcer. This is exactly what we observed when we 
compared the predictive performance of NetMHCII-2.3 and NetMHCpan-3.2. Earlier work has shown a similar 
result, namely that when allele-specific neural network prediction algorithms rely on a sufficient number of 
peptide binders they achieve high predictive performances (33),(35). This illustrates how the allele-specific 
method is preferable only if a large amount of data is available for the MHC molecule in question, while 
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highlighting the strength of the pan-specific methods, which can benefit from data of related MHC molecules 
to make reliable predictions for MHC molecules with limited data. Because of this difference between the 
allele-specific and the pan-specific method, we implemented a simple combination of two methods as this has 
been shown to improve the predictive performance for MHC class I molecules (33). This analysis showed that 
NetMHCIIpan-3.2 outperforms NetMHCII-2.3 for MHC molecules which have been trained with very few 
peptides, but that a combination of the predictions from the two MHC class II methods still outperformed each 
individual method. 
 
Leave-one-molecule-out performance for NetMHCIIpan 
One of the main powers of the NetMHCIIpan method is that it can predict binding affinities for 
uncharacterized MHC molecules. To assess the performance of the method in such a task, we constructed a 
LOMO experiment where we tested the performance of the NetMHCIIpan method for predicting binding 
affinity for MHC molecules not included in the training data for the method. From this analysis, we could show 
that the pan-specific method is capable of prediction binding affinity for MHC molecules where no binding 
affinity data is available and further demonstrate that the predictive performance is dependent on the 
distance to the nearest neighbor. This last observation indicated that the predictive performance of the 
NetMHCIIpan method could be further improved by including more uncharacterized MHC molecules into the 
training data and it is therefore important to generate experimental peptide binding affinity data points in a 
targeted fashion for MHC molecules not yet characterized.  
 
Distance tree for HLA class II molecules 
To understand the different groups of HLA class II molecules, we generated a fictional distance tree using 
NetMHCIIpan-3.2. The groups shown in this distance tree can be used to understand how peptides interact 
with different MHC molecules and can be used to discriminate between binders and non-binders. The distance 
tree can also be used to identify T-cell epitopes with similar properties important for the design of epitope-
based vaccines. Another aspect that can be observed for the tree is that most MHC molecules have strong 
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anchor positions at P1, P4, P6 and P9 which have also been observed in previous studies (8).  
 
T-cell epitope benchmark 
Accurate predictions of peptide binding affinities to MHC molecules are important for understanding the cell 
mediated immune response and for generating better screening methods for cost-effective identification of 
immunogenic peptides. We therefore wanted to test the predictive performance of the two versions of 
NetMHCIIpan on a T-cell epitope data set, and doing this we demonstrated how the new version of 
NetMHCIIpan obtained a significantly improved predictive performance compared to the earlier version. Two 
main factors explain this performance gain: i) including data for new MHC-II molecules decrease the distance 
to the nearest neighbor, ii) including an increased number of data points allow the method better 
characterizing the specificity of a given MHC-II molecule.  
In conclusion, we believe that NetMHCII and NetMHCIIpan can be used to improve MHC-II binding predictions 
and reduce experimental costs for immunologists working within the field of epitope-based vaccine design, 
and to improve our knowledge about the peptide-MHC interaction, a key event in the cellular immune 
response. 
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Figure legends: 
Figure 1: Performance of NetMHCII-2.3 and NetMHCIIpan-3.2 together with the combination method. (A) The 
average performance per MHC molecule of NetMHCII-2.3, NetMHCIIpan-3.2 and the combination method, 
including the significance between the methods. P-values where found using a paired T-test using the 
predictions per molecule found in supplementary table 3. (B) The average predictive performance of the MHC 
molecules in the data set as a function of the number of peptides. 
 
Figure 2: Predictive performance for NetMHCIIpan-3.2 LOMO on the MHC class II molecules from the 2016 
data set as a function of distance to the nearest neighbor. Each HLA II isotype and H-2 molecules are displayed 
in different colors and the dashed line represents the least square fit for the data. 
 
Figure 3: Distance tree for all HLA molecules found in our data set generated using the MHCCluster method. 
Sequence logos shows the motif of the predicted binding core for each HLA and were generated using 
Seq2Logo (30). The names are colored according to the type of HLA, HLA-DR in red, HLA-DQ in blue and HLA-
DP in green. 
 
Figure 4: Performance of NetMHCIIpan-3.1 and NetMHCIIpan-3.2 using the T-cell epitope benchmark set. (A) 
The average Frank performance per MHC molecule for the two versions of NetMHCIIpan. (B) The average AUC 
performance per MHC molecule for the two versions of NetMHCIIpan. (C) The change in the distance to the 
nearest neighbor between the two data sets used for training the old and the new version of NetMHCIIpan as 
a function of the change in distance to the nearest neighbor. (D) the change in the number of data points 
between the two data sets used for training NetMHCIIpan-3.1 and NetMHCIIpan-3.2 as a function of the 
change in the performance, including only MHC molecules where the pseudo sequence did not change 
between two data sets. The dashed line in the two scatterplots represents the least square fit for the data.  
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Table 1: Description of the two MHC class II peptide binding data sets.  
 
Table 2: Comparing prediction from the old and the new versions of NetMHCII and NetMHCIIpan trained using 
a five-fold cross-validation on the set of data points common between the two data sets. For each MHC 
molecule, we show the total number of peptides, the number of binders, the AUC performance. The different 
methods included are the NetMHCII and NetMHCIIpan methods training on the original 2013 data set 
(versions 2.2 and 3.1), and the versions of the two methods trained on the extended 2016 data set (versions 
2.3 and 3.2). The highest performance for NetMHCII and NetMHCIIpan is highlighted in bold. 
 
Table 3: Comparing predictions from the old (versions 2.2 and 3.1), and the new version (versions 2.3 and 3.2), 
of NetMHCII and NetMHCpan using the 5-fold cross-validation setup and evaluating on the subset of new 
peptides using only MHC molecules shared between the 2013 and 2016 data sets. For each MHC molecule, we 
show the total number of peptides, the number of binders and the AUC performance for the different 
versions. Highlighted in bold is the highest performance between the two NetMHCII and NetMHCIIpan 
methods.  
 
Table 4: Comparing prediction from the old and the new version of NetMHCIIpan using the 5-fold cross-
validation setup on the set of MHC molecules found in the 2016 data set but not in the 2013 data set. For each 
molecule, we show the total number of peptides, the number of binders and the AUC performance for the two 
NetMHCIIpan versions. In bold is highlighted the highest performance of the two versions 3.1 and 3.2 of 
NetMHCIIpan. Highlighted in bold is the highest performance between the two methods. 
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Table 5: Comparing leave-one-molecule-out predictions from the old and the new method on the set of data 
points common between the two data sets. For each molecule, we show the number of peptides, the number 
of binders, the AUC performance for the old (3.1) and new (3.2) methods, and the distance to the nearest 
neighbor for the old and new data set. Nearest neighbors are found from the subset of molecules in the 
training data characterized with at least 50 data points and at least 10 binders. Highlighted in bold is the 
highest performance between the two methods. 
 
  
  
 
 
 
 
  Data set 2013 Data set 2016 
# data points  52062 134281 
Type of alleles 
24 HLA-DR 36 HLA-DR 
6 HLA-DQ 27 HLA-DQ 
5 HLA-DP 9 HLA-DP 
2 H-2 8 H-2 
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Molecule  #peptides #binders NetMHCII-2.2 NetMHCII-2.3 NetMHCIIpan-3.1 NetMHCIIpan-3.2 
DRB1_0101 2754 2635 0.817 0.822 0.828 0.830 
DRB1_0301 1403 379 0.832 0.826 0.829 0.835 
DRB1_0401 1639 695 0.801 0.791 0.804 0.798 
DRB1_0404 542 331 0.783 0.768 0.813 0.810 
DRB1_0405 1438 595 0.862 0.860 0.852 0.844 
DRB1_0701 1619 806 0.858 0.857 0.852 0.857 
DRB1_0802 1310 400 0.757 0.767 0.753 0.749 
DRB1_0901 841 560 0.746 0.761 0.777 0.779 
DRB1_1101 1604 730 0.876 0.876 0.875 0.876 
DRB1_1302 1351 463 0.811 0.823 0.801 0.810 
DRB1_1501 1601 672 0.818 0.820 0.817 0.831 
DRB3_0101 1266 267 0.835 0.846 0.835 0.824 
DRB4_0101 1329 467 0.840 0.841 0.832 0.817 
DRB5_0101 1606 765 0.852 0.847 0.855 0.846 
H-2-IAb 525 125 0.850 0.857 0.849 0.868 
H-2-IAd 100 24 0.718 0.809 0.734 0.808 
HLA-DPA10103-DPB10401 1075 458 0.957 0.960 0.956 0.961 
HLA-DPA10201-DPB10101 1180 558 0.949 0.949 0.949 0.948 
HLA-DPA10201-DPB10501 1114 415 0.957 0.954 0.949 0.948 
HLA-DPA10301-DPB10402 1193 498 0.958 0.957 0.957 0.952 
HLA-DQA10101-DQB10501 990 246 0.856 0.890 0.834 0.857 
HLA-DQA10102-DQB10602 1121 503 0.838 0.901 0.877 0.887 
HLA-DQA10301-DQB10302 1461 330 0.824 0.820 0.796 0.774 
HLA-DQA10401-DQB10402 1436 516 0.919 0.923 0.915 0.903 
HLA-DQA10501-DQB10201 1386 477 0.898 0.901 0.886 0.883 
HLA-DQA10501-DQB10301 1274 530 0.893 0.873 0.881 0.860 
Average      0.856 0.863 0.856 0.858 
 
Table 2 
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Molecule #peptides #binders NetMHCII-2.2 NetMHCII-2.3 NetMHCIIpan-3.1 NetMHCIIpan-3.2 
DRB1_0101 7909 3975 0.855 0.816 0.839 0.824 
DRB1_0301 4086 1120 0.805 0.813 0.783 0.812 
DRB1_0401 4849 2391 0.780 0.799 0.776 0.812 
DRB1_0404 3169 1549 0.715 0.787 0.763 0.810 
DRB1_0405 2663 1120 0.809 0.832 0.817 0.819 
DRB1_0701 4862 2727 0.828 0.882 0.829 0.880 
DRB1_0802 3273 1669 0.804 0.845 0.829 0.854 
DRB1_0901 3578 1662 0.845 0.843 0.835 0.839 
DRB1_1101 4610 2018 0.833 0.864 0.825 0.862 
DRB1_1302 3259 1824 0.858 0.906 0.864 0.905 
DRB1_1501 3392 1497 0.814 0.840 0.821 0.836 
DRB3_0101 3497 1177 0.899 0.911 0.898 0.904 
DRB4_0101 2764 1121 0.804 0.836 0.810 0.823 
DRB5_0101 3681 1738 0.841 0.849 0.843 0.849 
H-2-IAb 1364 306 0.942 0.900 0.926 0.909 
H-2-IAd 683 297 0.767 0.820 0.803 0.821 
HLA-DPA10103-DPB10201 784 140 0.968 0.909 0.954 0.917 
HLA-DPA10103-DPB10401 1804 328 0.897 0.907 0.895 0.906 
HLA-DPA10201-DPB10101 1382 301 0.838 0.847 0.846 0.861 
HLA-DPA10201-DPB10501 1537 298 0.869 0.872 0.839 0.873 
HLA-DPA10301-DPB10402 1591 423 0.858 0.858 0.859 0.861 
HLA-DQA10101-DQB10501 2122 569 0.937 0.935 0.928 0.926 
HLA-DQA10102-DQB10602 1710 753 0.868 0.919 0.890 0.910 
HLA-DQA10301-DQB10302 1790 238 0.863 0.878 0.851 0.843 
HLA-DQA10401-DQB10402 1620 412 0.810 0.876 0.810 0.875 
HLA-DQA10501-DQB10201 1656 397 0.849 0.884 0.851 0.881 
HLA-DQA10501-DQB10301 2379 1282 0.915 0.947 0.926 0.946 
Average 
  
0.847 0.866 0.849 0.865 
 
Table 3 
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Molecule  #peptides #binders NetMHCIIpan-3.1  NetMHCIIpan-3.2  
DRB1_0103 42 4 0.664 0.678 
DRB1_0402 53 19 0.680 0.701 
DRB1_0403 59 14 0.767 0.841 
DRB1_0801 937 390 0.839 0.844 
DRB1_1001 2066 1521 0.907 0.923 
DRB1_1104 27 5 0.682 0.791 
DRB1_1301 1034 520 0.727 0.857 
DRB1_1502 23 7 0.688 0.652 
DRB1_1602 1699 989 0.827 0.883 
DRB3_0202 3334 1055 0.789 0.869 
DRB4_0103 846 525 0.786 0.841 
H-2-IAk 115 4 0.426 0.635 
H-2-IAs 190 48 0.438 0.825 
H-2-IAu 56 22 0.790 0.765 
H-2-IEd 245 28 0.623 0.754 
H-2-IEk 68 40 0.881 0.853 
HLA-DPA10103-DPB10301 1563 575 0.588 0.902 
HLA-DPA10103-DPB10402 45 9 0.815 0.710 
HLA-DPA10103-DPB10601 584 282 0.996 0.995 
HLA-DPA10201-DPB11401 2302 849 0.696 0.930 
HLA-DQA10102-DQB10501 833 458 0.606 0.839 
HLA-DQA10102-DQB10502 800 158 0.825 0.835 
HLA-DQA10103-DQB10603 462 90 0.802 0.861 
HLA-DQA10104-DQB10503 883 105 0.787 0.805 
HLA-DQA10201-DQB10202 944 119 0.779 0.814 
HLA-DQA10201-DQB10301 827 374 0.813 0.849 
HLA-DQA10201-DQB10303 761 265 0.743 0.894 
HLA-DQA10201-DQB10402 768 241 0.529 0.860 
HLA-DQA10301-DQB10301 207 66 0.822 0.839 
HLA-DQA10303-DQB10402 567 117 0.483 0.820 
HLA-DQA10501-DQB10302 847 203 0.772 0.822 
HLA-DQA10501-DQB10303 564 179 0.809 0.876 
HLA-DQA10501-DQB10402 749 337 0.584 0.868 
HLA-DQA10601-DQB10402 565 133 0.498 0.848 
Average      0.719 0.826 
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   NetMHCIIpan-3.1-LOMO NetMHCIIpan-3.2-LOMO 
Molecule #peptides #binders AUC Pseudo 
distance 2013 
AUC Pseudo 
distance 
2016 
DRB1_0101 2717 2599 0.735 0.22 0.765 0.16 
DRB1_0301 1403 379 0.726 0.11 0.739 0.14 
DRB1_0401 1639 695 0.757 0.04 0.769 0.04 
DRB1_0404 542 331 0.765 0.06 0.773 0.03 
DRB1_0405 1438 594 0.822 0.04 0.819 0.04 
DRB1_0701 1619 806 0.816 0.28 0.814 0.27 
DRB1_0802 1310 400 0.678 0.03 0.700 0.03 
DRB1_0901 841 560 0.698 0.25 0.713 0.25 
DRB1_1101 1604 730 0.720 0.06 0.770 0.06 
DRB1_1302 1351 463 0.652 0.06 0.662 0.05 
DRB1_1501 311 100 0.734 0.20 0.802 0.13 
DRB3_0101 1266 267 0.685 0.12 0.690 0.14 
DRB4_0101 1329 467 0.752 0.27 0.716 0.00 
DRB5_0101 1606 765 0.802 0.20 0.805 0.20 
H-2-IAb 39 20 0.818 0.34 0.842 0.34 
H-2-IAd 107 24 0.778 0.34 0.820 0.34 
HLA-DPA10103-DPB10201 5 1 1.000 0.06 1.000 0.06 
HLA-DPA10103-DPB10401 1075 458 0.942 0.06 0.952 0.06 
HLA-DPA10201-DPB10101 1180 558 0.935 0.07 0.927 0.07 
HLA-DPA10201-DPB10501 1114 415 0.933 0.07 0.938 0.07 
HLA-DPA10301-DPB10402 1193 498 0.934 0.09 0.934 0.11 
HLA-DQA10101-DQB10501 990 246 0.741 0.23 0.687 0.02 
HLA-DQA10102-DQB10602 1121 503 0.553 0.23 0.786 0.07 
HLA-DQA10301-DQB10302 1461 330 0.645 0.19 0.619 0.09 
HLA-DQA10401-DQB10402 1436 516 0.875 0.26 0.690 0.02 
HLA-DQA10501-DQB10201 1386 477 0.547 0.27 0.761 0.07 
HLA-DQA10501-DQB10301 1274 530 0.442 0.19 0.647 0.06 
Average   0.759  0.783  
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